dc.contributor.author |
Wright, Daniel FB |
en |
dc.contributor.author |
Duffull, Stephen B |
en |
dc.contributor.author |
Merriman, Tony R |
en |
dc.contributor.author |
Dalbeth, Nicola |
en |
dc.contributor.author |
Barclay, Murray L |
en |
dc.contributor.author |
Stamp, Lisa K |
en |
dc.date.accessioned |
2018-10-17T23:51:26Z |
en |
dc.date.issued |
2016-02 |
en |
dc.identifier.citation |
Br J Clin Pharmacol, 2015 |
en |
dc.identifier.issn |
0306-5251 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/42748 |
en |
dc.description.abstract |
AIMS:The primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of ≤0.36 mmol l(-1) . METHODS:A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. RESULTS:The urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. CONCLUSIONS:Contrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
British journal of clinical pharmacology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Humans |
en |
dc.subject |
Gout |
en |
dc.subject |
Oxypurinol |
en |
dc.subject |
Allopurinol |
en |
dc.subject |
Uric Acid |
en |
dc.subject |
Gout Suppressants |
en |
dc.subject |
Predictive Value of Tests |
en |
dc.subject |
Dose-Response Relationship, Drug |
en |
dc.subject |
Models, Biological |
en |
dc.subject |
Middle Aged |
en |
dc.subject |
Female |
en |
dc.subject |
Male |
en |
dc.subject |
Clinical Trials as Topic |
en |
dc.title |
Predicting allopurinol response in patients with gout. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/bcp.12799 |
en |
pubs.issue |
2 |
en |
pubs.begin-page |
277 |
en |
pubs.volume |
81 |
en |
dc.identifier.pmid |
26451524 |
en |
pubs.end-page |
289 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
research-article |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
501967 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
dc.identifier.eissn |
1365-2125 |
en |
pubs.record-created-at-source-date |
2015-10-10 |
en |
pubs.dimensions-id |
26451524 |
en |